Fig 1.
Flow chart of exclusions and analytic groups in gene expression analyses.
Bold text indicates analyzed groups. The group “All EOC by time to diagnosis” was used in the analysis of all EOC adjusted for leukocyte populations.
Table 1.
Participant characteristics on day of blood sample collection.
Table 2.
Distribution of epithelial ovarian cancer (EOC) cases in analytical groups (bold text) of case-control differences in gene expression.
Fig 2.
Overlap between the 100 probes with lowest p-values in single-gene linear models (case-control) of prospective blood samples from all cases of epithelial ovarian cancer (EOC; 66 pairs) and subgroups (metastatic at diagnosis (56 pairs), serous subtype (45 pairs), or interval to diagnosis (≤3 years or >3 years; 34 and 31 pairs, respectively)).
The 100 probes are listed in S2–S6 Tables. (Created with BGE Venn diagram tool, Ghent University).
Table 3.
Probes with the 20 greatest absolute log2FC valuesa among the 100b lowest p-values in single-gene linear models (case-control) of prospective blood samples from all cases of epithelial ovarian cancer (EOC) and subgroup analyses by clinicopathologic characteristics and interval to diagnosis.
Fig 3.
Gene Ontology (GO) enrichment of biological processes among the 100 probes with the lowest p-values in single-gene linear models (case-control) of blood samples from all cases of epithelial ovarian cancer (66 pairs) and according to metastasis status (56 pairs), serous subtype (45 pairs), and interval to diagnosis (≤3 years or >3 years; 34 and 31 pairs, respectively).
Numbers below each column indicate the number of probes for which GO categories could be found. The figure presents the five GO categories with lowest p-values. Enriched GO categories (p<0.05) beyond the top five are included in addition if they are among the five most enriched of one of the other investigated groups. S8 Table presents the complete GO enrichment list.